+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Utilization and determinants of adjuvant therapy among older patients who receive curative surgery for pancreatic cancer



Utilization and determinants of adjuvant therapy among older patients who receive curative surgery for pancreatic cancer



Pancreas 38(1): E18-E25



We conducted a population-based study to describe the utilization, determinants, and survival effects of adjuvant therapies after surgery among older patients with pancreatic cancer. Using Surveillance, Epidemiology, and End Results-Medicare data, we identified patients older than 65 years who received surgical resection for pancreatic cancer during 1992-2002. We constructed multiple logistic regression models to examine patient, clinical, and hospital factors associated with receiving adjuvant therapy. Cox proportional hazards models were used to examine the effect of therapy on survival. Approximately 49% of patients received adjuvant therapy after surgery. Patient factors associated with increased receipt of adjuvant therapy included more recent diagnosis, younger age, stage II disease, higher income, and geographic location. Hospital factors associated with increased receipt of adjuvant therapy included cooperative group membership and larger size. Adjuvant treatments associated with a significant reduction in 2-year mortality (relative to surgery alone) were chemoradiation or radiation alone but not chemotherapy alone. Our findings suggest that adjuvant chemoradiation and, to a lesser degree, radiation only are associated with a reduction in the risk of mortality among older patients who undergo surgery for pancreatic cancer. However, receipt of adjuvant therapy varied by period and geography as well as by certain patient and hospital factors.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 056824047

Download citation: RISBibTeXText

PMID: 18797424

DOI: 10.1097/MPA.0b013e318187eb3f


Related references

The Lymph Node Ratio Is an Independent Prognostic Factor in Pancreatic Cancer Patients Who Receive Curative Resection Followed by Adjuvant Chemotherapy. Anticancer Research 38(8): 4877-4882, 2018

Clinical significance of IGF1R gene expression in patients with Stage II/III gastric cancer who receive curative surgery and adjuvant chemotherapy with S-1. Journal of Cancer Research and Clinical Oncology 142(2): 415-422, 2016

Should patients with Dukes' C colon cancer receive adjuvant chemotherapy after curative resection?. Australian and New Zealand Journal of Surgery 61(1): 7-11, 1991

Glasgow Prognostic Score Predicts Clinical Outcomes in Patients with Pancreatic Cancer Undergoing Adjuvant Gemcitabine Monotherapy After Curative Surgery. Anticancer Research 35(9): 4865-4870, 2016

Should all patients with node-negative breast cancer receive adjuvant therapy? Identifying additional subsets of low-risk patients who are highly curable by surgery alone. Cancer 68(7): 1482-1494, 1991

Impact of the interval between surgery and radiotherapy in the initial phases of breast cancer in patients who did not receive systemic adjuvant therapy. Ginecologia Y Obstetricia de Mexico 66: 87-91, 1998

Clinical Significance of INHBA Gene Expression in Patients with Gastric Cancer who Receive Curative Resection Followed by Adjuvant S-1 Chemotherapy. In Vivo 31(4): 565-571, 2018

Role of adjuvant surgery for patients with initially unresectable pancreatic cancer with a long-term favorable response to non-surgical anti-cancer treatments: results of a project study for pancreatic surgery by the Japanese Society of Hepato-Biliary-Pancreatic Surgery. Journal of Hepato-Biliary-Pancreatic Sciences 20(6): 590-600, 2016

Su1547 Failure to Receive Adjuvant Therapy Following Resection for Pancreatic Cancer: Patterns and Implications. Gastroenterology 142(5): S-1059-S-1060, 2012

Adjuvant therapy with WT1 peptide-pulsed dendritic cell therapy in combination with TS-1 for pancreatic cancer with positive peritoneal cytology after curative operation. Gan to Kagaku Ryoho. Cancer and ChemoTherapy 41(10): 1298-1300, 2014

Adjuvant therapy following curative surgery of colon cancer. Aktuelle Probleme in Chirurgie und Orthopadie 1979(10): 61-70, 1979

Improving adjuvant therapy for rectal cancer by combining protracted-infusion fluorouracil with radiation therapy after curative surgery. New England Journal of Medicine 331(8): 502-507, 1994

Efficacy of surgery and adjuvant therapy in older patients with colorectal cancer: a STROBE-compliant article. Medicine 93(28): E266, 2015

Should all stage II and III rectal cancer patients receive the same adjuvant therapy?. Gastroenterology 112(4 SUPPL ): A606, 1997

Determinants of Rectal Cancer Patients' Decisions on Where to Receive Surgery: a Qualitative Analysis. Journal of Gastrointestinal Surgery 2018, 2018